Navigation Links
Lexicon Announces Pricing of Common Stock in Public Offering

THE WOODLANDS, Texas, March 16 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the pricing of a public offering and concurrent private placement of its common stock in which  the aggregate net proceeds to Lexicon will be approximately $165.0 million.  The public offering consists of 87,717,391 shares of its common stock at a public offering price of $1.15 per share.  In connection with the public offering, Lexicon agreed to sell an additional 59,296,749 shares of its common stock at the public offering price to Invus, L.P., Lexicon's largest stockholder, in a concurrent private placement upon Invus' exercise of its right to purchase shares sufficient to maintain its pro rata ownership of Lexicon's common stock.

All of the shares subject to the public offering are being offered by Lexicon pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission.  Lexicon has also granted the underwriters a 30-day option to purchase up to an aggregate of 8,804,348 additional shares of common stock to cover over-allotments, if any.  To the extent the underwriters exercise their over-allotment option, Invus may purchase up to an aggregate of 5,951,718 additional shares of common stock in a private placement pursuant to its right to purchase shares sufficient to maintain its pro rata ownership of Lexicon's common stock.  Morgan Stanley & Co. Incorporated and J.P. Morgan Securities Inc. are acting as joint book-runners for the public offering, with Cowen and Company, LLC and Thomas Weisel Partners LLC acting as co-managers.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted.  The offering of the securities in the public offering will be made only by means of a final prospectus supplement and accompanying prospectus, copies of which may be obtained from Morgan Stanley & Co. Incorporated, Attn:  Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, telephone:  (866) 718-1649, or by emailing, or from J.P. Morgan Securities, Inc., Attention:  Broadridge Financial Solutions at 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at (866) 803-9204.

The issuer has filed a registration statement (including a base prospectus) with the Securities and Exchange Commission, or SEC, for an offering to which this communication relates.  Before you invest, you should read the prospectus in that registration statement and related prospectus supplements and other documents that the issuer has filed or will file with the SEC for more complete information about the issuer and this offering.  You may get these documents for free by visiting EDGAR on the SEC website at  Alternatively, you may obtain a final prospectus supplement and accompanying prospectus as indicated above.

The shares to be sold to Invus in the private placement have not been, and will not be, registered under the Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States absent registration or applicable exemption from the registration requirement of such Act and applicable state securities laws.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome, and rheumatoid arthritis, all of which were discovered by the company's research team.  

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements related to Lexicon's expectations regarding the completion, timing and size of the public offering and concurrent private placement. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.  Words such as "anticipated," "will," "proposed," and similar expressions are intended to identify these forward-looking statements.  There are a number of important factors that could cause Lexicon's results to differ materially from those indicated by these forward-looking statements, including risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the public offering and concurrent private placement.  There can be no assurance that Lexicon will be able to complete the public offering or concurrent private placement on the anticipated terms, or at all.  Additional risks and uncertainties relating to the public offering and concurrent private placement, Lexicon and its business can be found under the headings "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission and under the heading "Risk Factors" in the final prospectus supplement related to the public offering to be filed with the Securities and Exchange Commission.  Unless required by applicable law, Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.

Back to top



SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
2. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
3. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
5. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
6. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
7. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
8. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
9. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
10. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
11. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
Post Your Comments:
(Date:10/8/2015)... Maryland , October 8, 2015 ... .   --> Goldman Small ... in the small cap and microcap sectors, announced ... research report on PharmaCyte Biotech, Inc. (OTCQB - ... focused on developing and preparing treatments for cancer ...
(Date:10/8/2015)... , Oct. 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, today ... partnering meetings taking place in the month of October: ... Partnering Forum RepliCel will be presenting at the ... on the Mesa to be held October 7-9 in ...
(Date:10/8/2015)... Claremont, CA (PRWEB) , ... October 08, 2015 ... ... by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and results ... abnormally viscous and sticky mucus accumulates in the lungs. This mucus is very ...
(Date:10/7/2015)... , Oct. 7, 2015  ChromaDex Corp. ... and nutritional ingredients that creates science-based solutions for ... nutrition, and pharmaceutical products, today announced that the ... CEO and Founder, is now available for on-demand ... -->   --> ...
Breaking Biology Technology:
... , ... , Formation of new blood ... been the focus of many drug screening and cell signaling research studies. Blood ... tumors, and is implicated in wound healing, retinopathy and macular degeneration. , ...
... , Tran T. Nham Varian Australia ... Introduction , Because ... with an ICP spectrometer, it has been widely used to determine trace ... work was to evaluate the ability of the ultrasonic nebulizer to handle ...
... Varian, Inc. , Introduction ... are veterinary drugs. The use of these in food production is ... and the European Union because of a possible increased cancer-risk through ... of nitrofurans contamination has been found in warm-water prawns, shrimp, and ...
Cached Biology Technology:
(Date:9/10/2015)... LONDON , Sept. 10, 2015 This ... dominate wearable technology products today, and emerging sensor types ... have risen through the peak of the wearable technology ... the slide to disillusionment. The common feature with all ... the key enabler for their most useful functions. Sensors ...
(Date:9/9/2015)... Columbia , Sept. 9, 2015  NuData ... organizational and solution-based milestones, furthering the company,s commitment ... of online fraud. NuData Security,s online ... enhancing the company,s growth cycle. The product combines ... to determine good user behavior from fraudulent behavior, ...
(Date:9/2/2015)... California , September 2, 2015 ... the security purpose implied in a system which ... geometry, voice, signature, iris, vein, DNA and finger ... has forced to develop such system which provides ... username, password, PIN, Patterns and tokens are vulnerable ...
Breaking Biology News(10 mins):
... MAMMALS could be at a greater risk of extinction due ... published today by the Zoological Society of London (ZSL). ... with information of where droughts and cyclones are most likely ... risk of exposure to extreme weather. The paper, published this ...
... WASHINGTON D.C. -- Secretary of Energy Steven Chu was among ... NSF,s Graduate Research Fellowship Program (GRFP) today. GRFP is ... engineering fields within NSF,s mission. It has been in ... in students with demonstrated potential for significant achievements in science ...
... synchronize their movements. For example, the footsteps of two ... consciously aware that it is happening. Similarly, the clapping ... Although this type of synchronous body movement has been ... social interactions remain obscure. In a new study, led ...
Cached Biology News:
... human XAB2 (amino terminus) XAB2 (XPA-binding ... interaction with XPA. Immunoprecipitation experiments have also ... with the transcription-coupled repair-specific proteins CSA and ... II. Microinjection experiments with XAB2 antibodies resulted ...
... maintenance, calibration, and validation (MCV) ... 96-well plate used for hands-free ... procedures using the Bio-Plex suspension ... is for use with Bio-Plex ...
Biology Products: